Companies that own Durect Corp.
First Eagle Investment Management LLC
22,476,546
13.87%
0
0.04%
06/30/2018
BlackRock Fund Advisors
10,067,509
6.21%
267,245
0%
06/30/2018
Ingalls & Snyder LLC
8,648,204
5.34%
0
0.5%
06/30/2018
The Vanguard Group, Inc.
6,623,282
4.09%
683,040
0%
06/30/2018
Renaissance Technologies LLC
3,269,494
2.02%
1,504,894
0%
06/30/2018
SSgA Funds Management, Inc.
2,426,997
1.5%
-9,280
0%
06/30/2018
Northern Trust Investments, Inc.
1,777,511
1.1%
162,977
0%
06/30/2018
PanAgora Asset Management, Inc.
1,720,977
1.06%
977,723
0.01%
06/30/2018
Geode Capital Management LLC
1,648,875
1.02%
270,967
0%
06/30/2018
Gagnon Securities LLC
1,483,035
0.92%
356,882
0.51%
06/30/2018
| Address |
10260 Bubb Road
Cupertino California 95014
United States
|
|
Employees
|
- |
| Website |
http://www.durect.com |
| Updated |
07/08/2019 |
| DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. Its product pipeline consists of multiple investigational drug candidates in clinical development. It offers DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery; and REMOXY ER, which provides investigational extended release pain relief. |
